Prophylaxis of gastrointestinal complications associated with the intake of antiplatelet age

Korneeva O.N.; Drapkina O.M.

doi:https://doi.org/

Korneeva O.N.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Klinika propedevtiki vnutrennikh bolezneĭ, gastroénterologii i gepatologii

Drapkina O.M.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Klinika propedevtiki vnutrennikh bolezneĭ, gastroénterologii i gepatologii

SPIN RSCI: 4456-1297
Scopus AuthorID: 57208852308
ResearcherID: G-8443-2016
ORCID: 0000-0002-4453-8430

Prophylaxis of gastrointestinal complications associated with the intake of antiplatelet age

Authors:

Korneeva O.N., Drapkina O.M.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2012;(2): 77‑82

Read: 85889 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Korneeva ON, Drapkina OM. Prophylaxis of gastrointestinal complications associated with the intake of antiplatelet age. Russian Journal of Evidence-Based Gastroenterology. 2012;(2):77‑82. (In Russ.)

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Use of alpha-glutamyl-tryptophan in patients with chronic atrophic autoimmune gastritis: interim study results. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):5-11

Early antithrombotic protection of the brain in patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):5-10

Study of drug-drug interactions between Mexidol and thrombolytic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):139-144

Abstract:

The application of antiplatelet agents considered to be indispensable components of modern therapy of coronary heart disease is associated with injuries to the mucous membrane of the gastrointestinal tract. The clinical studies have demonstrated that proton pump inhibitors (PPI) decrease the frequency of recurrent gastrointestinal hemorrhage in the patients belonging to the groups of high cardiological risk treated with antiplatelet medicines. It is emphasized that special caution is needed when prescribing such agents to the patients with PPI at risk of development of gastropathies taking into account their safety. The original pharmaceutical preparation pantoprazol (Сontroloc, Nycomed) is considered to be the drug of choice among PPI due to its minimal interaction with other medications, confirmed safety and efficacy.

Keywords:

antiplatelet therapy

aspirin

clopidrogel

pantoprazol

gastrointestinal hemorrhage

NSAID gastropathy

antiplatelet therapy

aspirin

clopidrogel

pantoprazol

gastrointestinal hemorrhage

drug interaction

NSAID gastropathy

drug interaction

Authors:

Korneeva O.N.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Klinika propedevtiki vnutrennikh bolezneĭ, gastroénterologii i gepatologii

Drapkina O.M.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Klinika propedevtiki vnutrennikh bolezneĭ, gastroénterologii i gepatologii

SPIN RSCI: 4456-1297
Scopus AuthorID: 57208852308
ResearcherID: G-8443-2016
ORCID: 0000-0002-4453-8430

Close metadata

References:

Rekomendatsii po antitromboticheskoi terapii u bol'nykh so stabil'nymi proyavleniyami ateroskleroza (podgotovleny E.P. Panchenko s uchastiem E.S. Kropachevoi). Aterotromboz 2009; 1 (2): 38-54.
Cryer B., Feldman M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal, anti-inflammatory drug-induced damage. Archive Intern Med 1992; 152: 1145-1155.
Soll A.H., Weinstein W.M., Kurata J., McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114: 307-319.
Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin North Am 1996; 6: 489-404.
Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000; 343: 1520-1528.
Peters R., Mehta S., Fox K., Zhao F., Lewis B.S., Kopecky S.L., Diaz R., Commerford P.J., Valentin V., Yusuf S. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108 (14): 1682-1687.
Laine L. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? Aliment Pharmacol Ther 2006; 24: 897-908.
Hallas J., Dall M., Andries A., Andersen B.S., Aalykke C., Hansen J.M. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case control study. BMJ 2006; 333: 726.
Lanza F., Chan F., Quigley E. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728-738.
Lapina T.L. Gastropatiya, indutsirovannaya nesteroidnymi protivovospalitel'nymi preparatami: puti resheniya problemy.- Bolezni organov pishchevareniya (prilozhenie RMZh) 2009; 2 (11): 12-14.
Rostom A., Wells G., Tugwell P., Welch V., Dube C., McGowan J. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000; 27: 2203-2214.
Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., Bujanda L., Gomollon F., Forne M. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507-515.
Bhatt D.L., Cryer B.L., Contant C.F., Cohen M., Lanas A., Schnitzer T.J., Shook T.L., Lapuerta P., Goldsmith M.A., Laine L., Scirica B.M., Murphy S.A., Cannon C.P. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med 2010; 363: 1909-1917.
Bhatt D.L., Scheiman J., Abraham N.S., Antman E.M., Chan F.K.L., Furberg C.D., Johnson D.A., Mahaffey K.W., Quigley E.M. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-1517.
Yavelov I.S. Rol' dvoinoi antitrombotsitarnoi terapii v konservativnom lechenii infarkta miokarda. Klin farmakol ter 2010; 19 (5): 23-32.
Farid N.A., Kurihara A., Wrighton S.A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50: 126-142.
Roden D.M., Stein C.M. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 2009; 119: 2127-2130.
Shuldiner A.R., O'Connell J.R., Bliden K.P., Gandhi A., Ryan K., Horenstein R.B., Damcott C.M., Pakyz R., Tantry U.S. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857.
Abraham N., Hlatky M., Antman E., Bhatt D.L., Bjorkman D.J., Clark C.B., Furberg C.D. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. J Am Coll Cardiol 2010; 56: 2051-2066.
O'Donoghue M.L., Braunwald E., Antman E.M., Murphy S.A., Bates E.R., Rozenman Y., Michelson A.D., Hautvast R.W., Ver Lee P.N., Close S.L., Shen L., Mega J.L., Sabatine M.S., Wiviott S.D. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
Dunn S.P., Macaulay T.E., Brennan D.M. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without use of clopidogrel in the CREDO trial. Circulation 2008; 118: S815. Abstract.
Ray W.A., Murray K.T., Griffin M.R., Chung C.P., Smalley W.E., Hall K., Daugherty J.R., Kaltenbach L.A., Stein C.M. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 15: 337-345.
Loginov A.F. Vybor ingibitora protonnoi pompy dlya profilaktiki i lecheniya NPVP-indutsirovannykh porazhenii zheludka. Klinicheskie perspektivy gastroenterologii i gepatologii 2009; 4: 13-21.
Sharova E.P. Preparat sanpraz (pantoprazol): opyt primeneniya v lechenii gastroezofageal'noi reflyuksnoi bolezni i drugikh kislotozavisimykh boleznei. Eksperimental'naya i klinicheskaya gastroenterologiya 2008; 6: 74-76.